Emerging drugs to treat Crohn's disease. - Test2 - elhamkhani - TriplyDB

Emerging drugs to treat Crohn's disease.

Emerging drugs to treat Crohn's disease.

http://www.wikidata.org/entity/Q39881787

about

Emerging drugs to treat Crohn's disease.

http://www.wikidata.org/entity/Q39881787

description

2010 nî lūn-bûn

@nan

2010年の論文

@ja

2010年学术文章

@wuu

2010年学术文章

@zh-cn

2010年学术文章

@zh-hans

2010年学术文章

@zh-my

2010年学术文章

@zh-sg

2010年學術文章

@yue

2010年學術文章

@zh

2010年學術文章

@zh-hant

name

Emerging drugs to treat Crohn's disease.

@en

Emerging drugs to treat Crohn's disease.

@nl

type

label

Emerging drugs to treat Crohn's disease.

@en

Emerging drugs to treat Crohn's disease.

@nl

prefLabel

Emerging drugs to treat Crohn's disease.

@en

Emerging drugs to treat Crohn's disease.

@nl

P1433

Q39881787-E0E254F5-17ED-489C-9D54-FF0090E0BD27

P1476

Q39881787-12F094BF-BAE0-4AF7-8474-B7BCACAADA41

P2093

Q39881787-78572006-2307-4A32-80D6-3B4378F13C7D

P2860

Q39881787-01606E89-2F3B-450E-866A-AF745E84A5FE

Q39881787-0366804F-5A8D-4817-B4B9-80D31815C53C

Q39881787-0578B89A-76AC-4CA0-B0E8-C46FE782A6BB

Q39881787-08135449-6C4B-47F1-AE27-FDB2ED61BD44

Q39881787-0ADB1472-0B50-4C99-866C-29877E0B6207

Q39881787-0B3ED76F-E362-4496-9929-5FC23CBAA811

Q39881787-0D99AEFF-8E59-48C0-ADE1-0DA0246F1C14

Q39881787-0DF07DC7-5443-4920-AA9B-A23E6A62D8E4

Q39881787-0E3C6793-90F4-4EEA-BAB7-E2BF8760DC18

Q39881787-0E4D955A-6BC7-4378-A62C-002CDB960D71

P304

Q39881787-EB1443BC-2086-4196-91B2-D19FBE69EBA9

P31

Q39881787-AC60A85D-F3B7-472C-B98D-14F6146FFD97

P356

Q39881787-B648665A-EE8C-4E32-AE68-D50C47E4FF8B

P407

Q39881787-60E640C6-F83C-4C46-855A-113B7E5AB585

P433

Q39881787-495B61F6-4AEB-4504-B764-48191721D126

P478

Q39881787-19557DF9-DA45-4316-A4BE-D9B5586A89F6

P50

Q39881787-5CF0E0DC-8D1C-4D4D-AB79-826EE62C4173

P577

Q39881787-45211111-9288-4CFC-B6A9-1C165B2A45C3

P698

Q39881787-6A3BED6D-5170-4A14-86BB-8CD8058E0B31

P356

14728214.2010.480972

P1433

Expert Opinion on Emerging Drugs

P1476

Emerging drugs to treat Crohn's disease.

@en

P2093

Ulrike Strauch

http://www.w3.org/2001/XMLSchema#string

P2860

Natalizumab Induction and Maintenance Therapy for Crohn's Disease

Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease

A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease

Adhesion molecules in inflammatory bowel disease

Common variants at five new loci associated with early-onset inflammatory bowel disease

Genome-wide association study identifies new susceptibility loci for Crohn disease and implicates autophagy in disease pathogenesis

A dose escalating, placebo controlled, double blind, single dose and multidose, safety and tolerability study of fontolizumab, a humanised anti-interferon gamma antibody, in patients with moderate to severe Crohn's disease

Integrins: bidirectional, allosteric signaling machines

Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease

A comparison of methotrexate with placebo for the maintenance of remission in Crohn's disease. North American Crohn's Study Group Investigators

P304

309-322

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1517/14728214.2010.480972

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

15

http://www.w3.org/2001/XMLSchema#string

P50

Jürgen Schölmerich

P577

2010-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

20402560

http://www.w3.org/2001/XMLSchema#string